Insider Selling: Stryker Co. (NYSE:SYK) Director Sells 201,392 Shares of Stock

Stryker Co. (NYSE:SYK) Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stryker Trading Down 0.1 %

Stryker stock opened at $390.97 on Tuesday. The stock has a market cap of $149.05 billion, a PE ratio of 50.38, a P/E/G ratio of 2.78 and a beta of 0.96. The stock has a 50-day moving average price of $376.68 and a 200 day moving average price of $363.22. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. Equities research analysts predict that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were issued a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s payout ratio is 43.30%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SYK shares. Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Citigroup boosted their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $419.37.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Zhang Financial LLC lifted its stake in shares of Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after purchasing an additional 40,784 shares in the last quarter. Dale Q Rice Investment Management Ltd acquired a new position in shares of Stryker in the 4th quarter valued at about $587,000. Berkshire Bank lifted its stake in shares of Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock valued at $3,056,000 after purchasing an additional 1,030 shares in the last quarter. PFW Advisors LLC acquired a new position in shares of Stryker in the 4th quarter valued at about $1,350,000. Finally, Traynor Capital Management Inc. acquired a new position in shares of Stryker in the 4th quarter valued at about $324,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.